GYRE logo

GYREGyre Therapeutics Inc

$5.95
$0.18
(2.94%)
Today
Closed $5.95
$0.00
(0.00%)
After Hours
Updated: 04:10 PM EDT
EarningsAug 10
Mkt Cap$594.57M
Vol71,008.00
46

Neutral Sentiment

How do you feel about GYRE?

News
all
press releases
New Strong Sell Stocks for May 27th
GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.
Zacks
News Placeholder
More News
News Placeholder
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of +16.67% and -33.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 2% - Should You Buy?
Gyre Therapeutics (NASDAQ:GYRE) Trading 2% Higher - Here's What Happened...
MarketBeat
News Placeholder
Gyre Therapeutics (GYRE) to Release Earnings on Tuesday
Gyre Therapeutics (NASDAQ:GYRE) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...
MarketBeat
News Placeholder
Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell
Zacks Research lowered shares of Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday...
MarketBeat
News Placeholder
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Time to Sell?
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Should You Sell...
MarketBeat
News Placeholder
Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) posted its earnings results on Thursday. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The...
MarketBeat
News Placeholder
Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold
Wall Street Zen cut Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...
MarketBeat
News Placeholder
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down - Should You Sell?
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down - What's Next...
MarketBeat
News Placeholder
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +2.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Advertisement|Remove ads.